期刊文献+

翼状胬肉术中应用bevacizumab与丝裂霉素C的比较 被引量:4

Comparative study of pterygium surgery combined with bevacizumab or mitomycin C
暂未订购
导出
摘要 目的:比较研究翼状胬肉手术联合bevacizumab与丝裂霉素C的临床疗效及其术后复发率和并发症情况。方法:将2010-01/2012-01浙江省中西医结合医院眼科住院的翼状胬肉患者80例随机分为两组,A组40例采用手术联合球结膜下注射bevacizumab治疗,B组40例采用手术联合术中丝裂霉素C贴敷治疗,随访1a,比较评估两组的临床疗效及其术后复发率和并发症。结果:A组治愈率为88%,B组为85%,两组临床疗效比较无显著差异(χ2=0.105,P>0.05);A组术后复发率为12%,B组为15%,两组术后复发率比较无显著差异(χ2=0.105,P>0.05);A组术后并发症发生率为2%,B组为18%,两组术后并发症比较有显著差异(χ2=4.517,P<0.05)。结论:翼状胬肉手术联合bevacizumab与丝裂霉素C的临床疗效显著,术后复发率低,但联合bevacizumab并发症较少。 AIM: To observe and compare the clinical effect and postoperative recrudescence rate and complication of pterygium surgery combined with bevacizumab or mitomycin C. METHODS: Eighty pterygium inpatients in the Department of Ophthalmology in Integrated Chinese and Western Medicine Hospital of Zhejiang Province from January 2010 to January 2012 were randomly divided into two groups. Forty cases in group A were treated by surgery combined with subconjunctival injection of bevacizumab, Forty cases in group B were treated by surgery combined with mitomycin C sticking therapy. After following up for 1 year, the curative effect and postoperative recurrence rate and complications were compared and evaluated between the two groups. RESULTS: The cure rate of group A and B were 88%, 85%, respectively, demonstrating no significant difference (χ2=0.105, P〉0.05);The postoperative recurrence rate of group A, B were 12%, 15%, respectively, the differences of which weren't significantly different (χ2 =0.105, P〉0.05); The incidence of postoperative complications in group A, B were 2%, 18%, the differences of which weren't significantly different (χ2=4.517, P〈0.05). CONCLUSION: The clinical effect of pterygium surgery combined with bevacizumab or mitomycin C is significant with a low postoperative recrudescence rate, but the former has fewer complications.
出处 《国际眼科杂志》 CAS 2013年第12期2532-2534,共3页 International Eye Science
关键词 翼状胬肉 BEVACIZUMAB 丝裂霉素C pterygium bevacizumab mitomycin C
  • 相关文献

参考文献18

  • 1Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol 1999,10(4) :282-288.
  • 2Kandavel R, Kang J J, Memarzadeh F, et al. Comparison of pterygium recurrence rates in Hispanic and white patients after primary excision and conjunctival autograft. Cornea 2010 ,29 ( 2 ) : 141 - 145.
  • 3Lei G. Surgery for pterygium using a eonjunctival peduneulated flap slide. Br J Ophthalmol 1996 ,80( 1 ) :33-34.
  • 4赵成,游志鹏.Avastin用于眼病治疗的新进展[J].中国实用眼科杂志,2009,27(2):101-104. 被引量:6
  • 5Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008 ,27 (9) :992-995.
  • 6Young AL, Tam PM, Leung GY, et al. Prospective study on the safety and efficacy of combined conjunctival rotational autograft with intraoperative 0. 02% mitomycin C in primary pterygium excision.Cornea 2009 ,28 ( 2 ) : 166-169.
  • 7Soliman MM, Bhatia J. Treatment of primary pterygium: role of limbal stem cells and conjunctival autograft transplantation. Eur J Ophthalmol 2009 , 19 ( 5 ) :729-732.
  • 8Busin M, Halliday BL, Arffa RC, et al. Precarved lyophilized tissue for lamellar keratoplasty in recurrent pterygium. Am J Ophthalmol 1986, 102(2) :222-227.
  • 9Prabhasawat P, Barton K, Burkett G, et al. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology 1997,104(6) :974-985.
  • 10Li X, Hu Y, Sun X, et al. Bevacizumab for neovascular age-related macular degeneration in China. Ovhthalmology 2012 , 119 (10) :2087 -2093.

二级参考文献30

  • 1罗晨美,孟英,王映芬,欧伟,林晨,黄培根.翼状胬肉成纤维细胞的体外培养[J].实用眼科杂志,1993,11(5):295-297. 被引量:50
  • 2Jonas JB,Spandau UH,Schlichtenbrede F,et al.Intravitreal bevacizumab combined with cataract surgery for treatment of exudative macular degeneration.J Ocul Pharmacol Ther, 2007,23 ( 6 ):599-600.
  • 3Charbel Issa P, Holz FG, Scholl HP.Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.Ophthalmology,2007,114 (9):1736-1742.
  • 4Shahar J, Avery RL, Heilweil G,et al.Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab ( Avastin ).Retina, 2006,26( 3 ):262-269.
  • 5Heiduschka P,Julien S,Hofmeister S,et al.Bevacizumab (Avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice.Retina, 2008,28( 1 ):46-55.
  • 6Ameri H, Chader G J, Kim JG, et al.The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits.Invest Ophthalmol Vis Sci, 2007,48( 12):5708-5715.
  • 7Falkenstein IA, Cheng L, Freeman WR.Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin).Retina, 2007,27 ( 8 ): 1044-1047.
  • 8Fung AE, Rosenfeld PJ, Reichel E.The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug Safety worldwide.Br J Ophthalmol, 2006,90( 11 ):1344-1349.
  • 9Grisanti S,Ziemssen F.Bevacizumab.Off-label use in ophthalmology. Indian J Ophthalmol, 2007,55:417-420.
  • 10Michels S,Rosenfeld PJ,Puliafito CA,et al.Systemic bevacizumab (Avastin)therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology, 2005,112(6):1035-1047.

共引文献14

同被引文献25

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部